FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux

Merck’s pembrolizumab demonstrates improvement in distant metastasis

Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).

USFDA approves first generic of Restasis

Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug

Medtronic partners with Stasis to enhance patient monitoring in India

The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors

FibroBiologics moves experimental psoriasis therapy into FDA review

The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting